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ChemotherapyDoxorubicin is one of the most important anti-cancer chemotherapeutic drugs, being widely used for the treat-
ment of solid tumors and acute leukemias. The action of doxorubicin and other anthracycline drugs has been
intensively investigated during the last several decades, but the mechanisms that have been proposed for cell
killing remain disparate and controversial. In this review, we examine the proposed models for doxorubicin
action from the perspective of the chromatin landscape,which is altered inmany types of cancer due to recurrent
mutations in chromatinmodiﬁers.We highlight recent evidence for effects of anthracyclines on DNA torsion and
chromatin dynamics that may underlie basic mechanisms of doxorubicin-mediated cell death and suggest new
therapeutic strategies for cancer treatment.
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Doxorubicin (also called adriamycin) belongs to a class of com-
poundswith similar structures, called anthracyclines. Like daunorubicin,
the ﬁrst anthracycline compound to be described, doxorubicin was iso-
lated from Streptomyces peucetius, a soil bacterium [1,2]. Doxorubicin
has shown great efﬁcacy in cancer cell killing for both solid and liquid
tumors, but the emergence of drug resistance and potential side effects
such as heart muscle damage after doxorubicin treatment are major
limitations for successful cancer treatment [3]. Despite the extensive
usage in the clinics, the molecular mechanism(s) by which doxorubicine.
Table 1
Actions of doxorubicin and their corresponding drug dose.
Doxorubicin dose a Reference
Topoisomerase II poisoning 0.4 μM [4]
DNA adduct formation 0.025 μM [25]
Free radical formation 0.1 μM [36]
Ceramide overproduction 0.3 μM [44]
Histone eviction 0.34 μM [11]
Cardiomyocyte apoptosis 0.1 μM [78]
Ovarian cancer cell apoptosis 0.5 μM [79]
a The drug dose varies between different cell types.
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the action of doxorubicin and related anthracycline drugs may provide
clues for enhancing cancer cell killing and reducing side effects. A num-
ber of models have been proposed for doxorubicin-mediated cell death,
including topoisomerase II poisoning, DNA adduct formation, oxidative
stress, and ceramide overproduction [4–6]. However, themodels remain
disparate and controversial. A deeper understanding of the basic molec-
ular interactions of doxorubicinwithin the cell is required to understand
how doxorubicin kills cancer cells and causes side effects.
Anthracycline drugs such as doxorubicin are mostly planar mole-
cules that preferentially intercalate between neighboring DNA base
pairs, anchored on one side by one or more sugar moieties that sit in
the DNAminor groove (Fig. 1). When DNA is topologically constrained,
as in the case of plasmid circles, the strand separation that occurs during
intercalation unwinds the double helix and produces DNA supercoils,
resulting in increased torsional stress. Linear genomes of eukaryotes
are partitioned into independent topological domains by protein factors
such as insulator binding protein CTCF [7], so each domain is topological
constrained. In vitro studies suggest that torsional stress can affect the
structure and dynamics of nucleosomes, the repeating unit of chromatin
composed of DNAwrapped around octameric histone cores [8,9]. Inter-
estingly, recent in vivo studies implicate doxorubicin in nucleosome
eviction and replacement [10,11]. Taken together, torsion-induced
nucleosome destabilization is emerging as a signiﬁcant molecular
mechanism for the action of doxorubicin and related anthracycline
drugs.
2. Models for doxorubicin-mediated cell death
A number of mechanisms have been proposed for doxorubicin-
mediated cell death. However, some of these such as inhibition of
DNA and RNA synthesis are only seen at doses higher than the clinical
dose (~40 to 60 mg/m2) [4] (Table 1). Here, we examine the proposed
mechanisms for doxorubicin action in clinically relevant drug doses.
2.1. Topoisomerase II poisoning
Topoisomerases are highly conserved enzymes that are present in
virtually all life forms, from bacteria to humans, and they regulate
DNA topology to facilitate DNA replication, transcription, and othera
Fig. 1. Structure of the doxorubicin-DNA complex. (a) Doxorubicin forms a covalent bond (sho
bondswith guanine on the opposing strand [77]. (b) A structure of intercalation of doxorubicin
the sugar moiety sitting in the minor groove.nuclear processes. Many anticancer and antibacterial drugs target
topoisomerases for cell killing, such as camptothecins, etoposide, and
quinolones [12]. The most parsimonious model for doxorubicin action
involves topoisomerase II poisoning, resulting in double-strand DNA
breaks and cell death at clinically relevant drug concentrations [3,4].
Topoisomerase II is an ATP-dependent enzyme that exists in two
isoforms in humans, topoisomerase IIα and topoisomerase IIβ. The
enzyme binds DNA supercoils and entangled DNA, breaks both strands
of one DNA duplex, passes the other duplex through the resulting gap
and reseals the break. This process results in the release of torsional
stress formed during biological processes such as DNA replication and
transcription (discussed below) [12]. In addition, topoisomerase II is
essential for decatenation of DNAduringmitosis, and deﬁciency in topo-
isomerase II prevents normal cytokinesis resulting in cell death [13].
Etoposide, a topoisomerase II poison, traps topoisomerase II at breakage
sites, stabilizes the cleavage complex and impedes DNA resealing [14].
Doxorubicin has been hypothesized to function in a similar way [15]
and it has been shown that topoisomerase II levels determine the effec-
tiveness of doxorubicin treatment in a mouse model of lymphoma [16].
However, there aremany examples inwhich doxorubicin-mediated cell
killing is independent of topoisomerase II. For example, doxorubicin
was shown to cause cell death independent of topoisomerase II in a
promyelocytic leukemic cell line [17]. In addition, doxorubicin as well
as another anthracycline drug, aclarubicin, which does not trap topo-
isomerase II, evicts histones independent of topoisomerase II leading
to cell death [10,18]. These ﬁndings suggest that anthracycline-
induced topoisomerase II poisoning by trapping topoisomerase II atb
wn in red) with guanine on one strand of DNA mediated by formaldehyde and hydrogen
into DNA. Doxorubicin intercalates into DNA and pushes apart the ﬂanking base pairs with
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by anthracycline drugs.
The anti-cancer activity of doxorubicin is attributable to killing of
dividing cells, where topoisomerase IIα is the major form of the
enzyme. However, heart muscle failure is a side effect that results
from damage to non-dividing cells, where topoisomerase IIβ is the
major form. Indeed, cardiomyocyte-speciﬁc deletion of topoisomerase
IIβ has been shown to protect mice from developing doxorubicin-
induced heart failure [19]. Inhibitors of topoisomerase II have also
been shown to protect cardiomyocytes from doxorubicin-induced
toxicity [20]. These ﬁndings suggest that trapping topoisomerase IIβ
by doxorubicin in non-dividing heart cells underlies doxorubicin-
induced cardiotoxicity.
2.2. DNA adduct formation
As a DNA intercalator, doxorubicin prefers the intercalation site
containing adjacent GC base pairs, probably due to speciﬁc hydrogen-
bond formation between doxorubicin and guanine (Fig. 1a) [21–23].
Formation of doxorubicin-DNA adducts has been shown to activate
DNAdamage responses and induce cell death independent of topoisom-
erase II [17,24]. Importantly, doxorubicin-DNA adducts are detectable at
clinically relevant drug concentrations, suggesting that doxorubicin-
DNA adducts form during chemotherapy [25]. The interaction between
doxorubicin and DNA can be stabilized by a covalent bondmediated by
cellular formaldehyde that is generated by free radical reactions from
carbon sources such as lipids and spermine [26,27]. This interaction
involves formation of a covalent bond between doxorubicin and
guanine on one strand of DNA mediated by formaldehyde and of a
hydrogen bond between doxorubicin and guanine on the opposing
strand (Fig. 1a). Interestingly, higher levels of formaldehyde have
been detected in doxorubicin-sensitive tumor cells compared to resis-
tant tumor cells and normal cells [28,29]. The formation of more
doxorubicin-DNA adducts might contribute to increased effectiveness
of the drug in doxorubicin-sensitive tumor cells.
The discovery of the covalent doxorubicin-DNA adduct has led to
a new approach to improve the anticancer activity of doxorubicin.
Compounds that release formaldehyde upon hydrolysis, such as
pivaloyloxymethyl butyrate (AN-9), butyroyloxymethyl-diethyl phos-
phate (AN-7), and hexamethylenetetramine (HMTA), have been devel-
oped and utilized in combination with doxorubicin. AN-9 showed a
synergy with doxorubicin in cancer cell killing as well as in overcoming
doxorubicin resistance to varying degrees by increasing DNA adduct
levels [30,31]. In addition, the combination of AN-7 and doxorubicin
has been shown to enhance its anticancer activity, to protect against
doxorubicin-induced toxicity in neonatal rat cardiomyocytes, and to
prevent weight loss in mice [32,33].
Despite the evidence that DNA adducts form during doxorubicin
treatment, DNA adduct formation is unlikely to be the major mecha-
nism of doxorubicin action, because clinical doses result in only
4.4 ± 1.0 adducts/107 base pair DNA, which accounts for just a small
fraction of total doxorubicin [25].
2.3. Oxidative stress
The quinone structure of doxorubicin can be oxidized to a
semiquinone radical through addition of one electron, mediated by a
number of NAD(P)H-oxidoreductases [5,34]. Semiquinone radicals
quickly react with oxygen to generate superoxide and hydrogen perox-
ide causing DNA damage. Additionally, doxorubicin is an iron chelator
and the doxorubicin-iron complex catalyzes the conversion of hydrogen
peroxide to highly reactive hydroxyl radicals [35]. Thus, doxorubicin-
induced release of free radicals may cause oxidative stress, resulting in
DNA damage and cell death [3].
A study using gas chromatography/mass spectrometry has shown
that after 72 to 96 h of slow intravenous infusion of doxorubicin witha steady level of 0.1 μM in the plasma, DNA base oxidation increased
up to 4-fold in peripheral blood mononuclear cells from breast cancer
patients [36]. Oxidized DNA bases were also detected in a cardiac cell
line and normal breast epithelial cells [37,38]. These ﬁndings suggest
that free radical-inducedDNAdamage indeed happens early after doxo-
rubicin treatment. If free radical formation accounts for doxorubicin-
mediated cell killing, free radical scavengers would rescue cell death
after doxorubicin treatment. Free radical scavengers have been used in
the clinic as protectants against doxorubicin-induced cardiotoxicity
but many of them failed, suggesting that free radical formation is not
the only mechanism of cardiotoxicity [39].
In addition to direct DNA damage by free radical formation, admin-
istration of low doses of doxorubicin can result in increased levels of
oxidative metabolism [40], which might have multiple effects on
components of the chromatin landscape. For example, 2-oxoglutarate
is involved in redox cycling reactions in cellular metabolism, and
is also the cofactor for JmjC domain-containing histone lysine
demethylases [41]. Another enzyme co-factor that is regulated by
oxidative metabolism is NAD(P), which is the substrate for ADP-
ribosylation reactions, including ADP-ribosylation of histones [42].
Although it is an intriguing possibility that the effects on chromatin by
alterations in these enzymes resulting fromdoxorubicin-induced oxida-
tive changes can lead to DNA damage, other possibilities need to be
considered. For example, when a histone acetyl group is removed by a
histone deacetylase (HDAC), the acetate anion that is released is
co-exported with a proton out of the cell, thus incrementally raising
the intracellular pH (pHi) [43]. The hyperacetylation of histones that
results from administration of histone deacetylase inhibitors prevents
release of acetate and protons, thus lowering pHi and potentially
decreasing cancer cell survivability in an acidic environment. So
although HDAC inhibitors have dramatic effects on global histone lysine
acetylation levels and can alter the chromatin landscape, these chroma-
tin effects might not be relevant to the anti-cancer effect of the drug. By
the same reasoning, potential effects of doxorubicin on histone modiﬁ-
cation might have as-yet undiscovered metabolic effects that are inde-
pendent of their effects on the chromatin landscape.
2.4. Ceramide overproduction
In addition to the generation of free radicals and the increase in
oxidative metabolism, doxorubicin treatment increases ceramide levels
[44–47]. Ceramide is a lipid molecule consisting of a sphingosine and a
fatty acid that is involved in a variety of cellular processes including
growth arrest, apoptosis, and senescence [6]. Interestingly, exogenous
cell-permeable ceramide sensitizes cancer cells to doxorubicin-
induced cell death [48]. In addition, doxorubicin treatment increases
ceramide levels in doxorubicin-sensitive MCF-7 cells but not in
doxorubicin-resistant MCF-7-AdrR cells, suggesting that ceramide
levels might mediate doxorubicin resistance. Indeed, up-regulation of
glucosylceramide synthase (GCS), an enzyme that converts ceramide
to glucosylceramide, is associated with cellular resistance to doxorubi-
cin, whereas suppression of GCS restores sensitivity to doxorubicin
resulting in cell death [49–52]. Recently, doxorubicin has been reported
to have a new role in blocking proliferation of cancer cells through
stimulation of ceramide synthesis and enhancement of proteolysis of a
membrane-boundprotein CREB3L1 [53]. Interestingly, CREB3L1 expres-
sion level is associatedwith cellular sensitivity to doxorubicin, although
its expression is not required for other anti-cancer drugs such as
etoposide, bleomycin, or paclitaxel to inhibit cell growth. Surprisingly,
no cell death was observed after doxorubicin treatment in this study
[53]. It is possible that inhibition of cell proliferation makes cells less
susceptible to doxorubicin, as doxorubicin preferentially kills dividing
cells. These ﬁndings suggest that ceramide overproduction might be
speciﬁcally involved in sensitizing cancer cells to doxorubicin treat-
ment, but this upstream effect is unlikely to involve changes in the
chromatin landscape.
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The disparate models described above underscore the controversies
surrounding the multiple modes of doxorubicin action within the cell.
Next we consider the possibility that the intercalation of doxorubicin
between DNA bases has a direct effect on chromatin that ultimately
results in cancer cell killing. Speciﬁcally, we focus on the consequences
of doxorubicin intercalation into DNA and ask what effect if any this
event might have on chromatin structure and dynamics.
3.1. DNA topology and chromatin
When an anthracycline molecule enters the cell, it diffuses into the
nucleus and intercalates into DNA. Anthracyclines are bound to DNA
so stably that daunorubicin autoﬂuorescence has been used by cytoge-
netics for Q-banding chromosomes, whereby AT-rich regions ﬂuoresce
brightly andGC-rich regions quench [54]. Intercalation of anthracyclines
pushes apart the ﬂanking base pairs (Fig. 1b). Because each base pair is
stacked in 36° counterclockwise rotation relative to the pair below,
intercalation has topological consequences. In covalently closed circular
DNA, the two strands are wound around each other a certain number of
times, called the linkingnumber (Lk).When theDNA circle is relaxed, Lk
is equal to the number of turns in the double helix, or the twist (Tw),
which is roughly 1 turn per 10.5 base pairs. Changes in the relaxed
value of Lk results in torsional stress that manifests itself as changes in
Tw and/or writhe (Wr), which is the number of times the double-
stranded DNA crosses itself, commonly known as supercoiling. Writhe
can be described as positive or negative, depending on whether
supercoiling occurs in right- or left-handed direction, respectively.
These topological aspects are most evident in bacteria, whose
circular genomes exist in a tightly regulated topological state. However,
linear genomes of eukaryotes can also be described using the same
topological terms, as the genome is partitioned into independent topo-
logical domains whose borders are restricted [7]. Thus, changes in Lk,
Tw, and Wr in one domain do not transfer to another. The wrapping
of the DNA around the octameric histones in a left-handed direction
generates one negative Wr per nucleosome. Thus, nucleosomes con-
strain negative supercoiling.
3.2. Torsional stress and nucleosome destabilization
Cellular processes that require access to DNA inevitably alter its
topological state, producing torsional stress. These processes include
DNA replication, transcription, recombination, and repair. During repli-
cation, helicases that separate the two strands alter the Lk and produce
torsional stress, resulting in waves of positive supercoiling downstream
of the helicase. Similarly, transcription by RNA Polymerase II (RNAPII)
results in denaturation of DNA at the transcription bubble. The
subsequent rotation of the DNA relative to RNAPII during transcription
creates domains of positive and negative supercoils downstream and
upstream, respectively, as predicted by the twin-supercoiled domain
model [55,56]. Furthermore, enzymes that remove or replace nucleo-
somes alter the supercoiling levels. For example, the nucleosome
remodeler SWI/SNF is known to generate negative supercoils [57,58].
Torsional stress can be detrimental, affecting the overall structure
and integrity of DNA. Furthermore, changes in Tw and/orWr can dereg-
ulate processes such as replication, transcription, and nucleosome
stability (discussed below). For example, accumulation of positive
torsion leads to transcriptional inhibition in over 80% of all genes in
yeast [59,60]. To counteract torsional stresses generated during various
DNA-based processes, cells utilize topoisomerases, thereby altering Lk.
As discussed above, doxorubicin can inhibit topoisomerase II in the
cleaved form and thus directly cause double-strand breaks. However,
as a DNA intercalator, doxorubicin primarily alters DNA topology. Single
molecule measurements show that intercalation of one doxorubicin
molecule relaxes the natural twist of the double helix by −27° [61],suggesting signiﬁcant underwinding in the presence of the drug. Such
a change in Tw in the negative direction introduces compensatory
positive torsional strain on the DNA. Increases in torsional stress can
affect many different processes, but because over 80% of eukaryotic
DNA is complexed in nucleosomes, perhaps the most immediate effect
is directly on nucleosome structure and dynamics.
Nucleosomes are quite sensitive to torsional changes. Single
molecule in vitro studies shows that nucleosome assembly stalls
when DNA is under positive torsional stress [62] whereas negative
supercoiling promotes assembly [63]. Another in vitro study showed a
preferential exchange of nucleosomes from positively- to negatively
supercoiled DNA [64]. Furthermore, the presence of positive torsional
stress seems to induce a structural change in the nucleosome, presum-
ably resulting in a more open complex where the H2A/H2B dimers
somewhat dissociate from the tetramer core [8,9]. This kind of
restructuring may render the nucleosome less stable.
3.3. Doxorubicin and nucleosome dynamics
The unwinding of DNA upon doxorubicin intercalationmay produce
sufﬁcient positive torsional stress to destabilize nucleosomes, which
would serve as a direct mechanism for action of the drug. Indeed, a
study from our laboratory tested this hypothesis using a recently devel-
oped strategy to measure nucleosome turnover, the disassembly and
subsequent reassembly of nucleosomes. Using metabolic labeling of
newly synthesized proteins followed by afﬁnity puriﬁcation, newly
incorporated H3/H4 core particles can be analyzed by tiling array or
next generation sequencing [65,66]. The method is called covalent
attachment of tags to capture histones and identify turnover, CATCH-
IT. By comparing nucleosome turnover proﬁles in mouse squamous
cell carcinoma cells before and after doxorubicin treatment at a concen-
tration of 0.34 μM, we found that doxorubicin enhances nucleosome
turnover around active gene promoters, despite a minor effect on
gene expression level. This enhancement is independent of the DNA
damage response proteins, p53 and ATM. This latter point is important
as p53 is mutated in many human cancers and both ATM and p53
have been implicated in the response of tumors to doxorubicin therapy
[67,68]. Interestingly, a similar effect on nucleosome turnover was
observed by treating the cells with another anthracycline drug,
aclarubicin, which inhibits topoisomerase II without causing DNA dou-
ble strand breaks [18] indicating that anthracycline drug intercalation
into DNA may play a direct role in enhancing nucleosome turnover
[11]. Another study showed that anthracycline drugs including doxoru-
bicin and aclarubicin, but not etoposide, evict histones from regions of
accessible chromatin in both human melanoma cell lines and acute
myeloid leukemia blasts from patients, leading to impairment of DNA
repair and apoptosis [10]. Additionally, this study found that 9 μM
doxorubicin evicts histones in topoisomerase IIα-depleted cells,
suggesting that topoisomerase IIα is not required for doxorubicin-
induced histone eviction [10]. Taken together, these studies suggest
that inhibition of topoisomerase II could further exacerbate torsional
strain by anthracycline drug intercalation, leading to enhancement of
nucleosome turnover downstream of promoters.
Topoisomerase inhibitors can have dramatic effects on chromatin-
associated processes, including replication and transcription. The
positive torsion generated aheadof RNApolymerase [55] canpotentially
unwrap nucleosomes, which are negatively supercoiled, and destabilize
them [69]. We have found that inhibitors of both topoisomerase I and II
cause both increased positive torsion and increased nucleosome turn-
over in gene bodies and vice-versa in intergenic regions of Drosophila
cells [70]. The net effect of topoisomerase-mediated enhancement of
torsion in gene bodies is to further destabilize nucleosomes during
RNA polymerase transit, thus increasing exposure of DNA to processes
that can cause DNA breaks, such as free radicals, and ultimately cell
death. Nucleosome destabilization might also be promoted by SWI/
SNF-class remodelers which act to evict nucleosomes at promoters,
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somes in gene bodies [71]. In this way, doxorubicin intercalation into
promoters and genesmight act by interferingwith the balance between
maintaining promoters free of nucleosomes while preventing loss of
nucleosomes during transcription. This model may account for the
observation that anthracycline drugs, including aclarubicin, increase
somatic recombination in a Drosophila in vivo assay for DNA damage
[72].
4. Future directions
Over the last several decades, many different modes of doxorubicin
action have been reported, which is consistent with the broad spectrum
of activity of the drug in cancer treatment. As discussed above, intercala-
tion of doxorubicin into DNA leading to torsional stress and nucleosome
destabilization may account for the basic mechanism of anthracycline-
mediated cell killing. Surveying the effects of other intercalating drugs
on chromatin structure and dissecting the mechanistic link between
this and cancer cell killing may lead to the development of better anti-
cancer drugs. Interestingly, another intercalating drug, voreloxin, a
quinolone derivative, has been recently found to act similarly to
anthracyclines in killing cancer cells, and intercalation is required for
voreloxin-mediated cell death [73]. Voreloxin holds promise as an alter-
native to anthracyclines, as it does not generate high levels of reactive
oxygen species, which can contribute to anthracycline-mediated
cardiotoxicity [39,73].
The fact that relatively high doses of anthracyclines (9 μM) used in
one study caused histone eviction and apoptosis [10], whereas low
sublethal doses (0.1 –0.4 μM) used in another study nevertheless
caused global nucleosome turnover and a DNA damage response [11],
raises the possibility that downward dosage adjustments might be
considered for current clinical protocols based on themaximum tolerated
dose. The effect of anthracyclines on destabilizing nucleosomes also
suggests that combining anthracyclines and other drugs that destabilize
nucleosomes may have synergistic effects in cancer cell killing. For
example, valproic acid, an HDAC inhibitor approved for clinical use as
an anticonvulsant and mood-stabilizing drug, increases the activity
of doxorubicin and leads to tumor regression and chromatin
decondensation when used in combination with another anthracycline
drug, epirubicin [74–76]. The development of new drugs that destabi-
lize nucleosomes have the potential of enhancing the therapeutic
efﬁcacy of anthracycline drugs while reducing side effects.
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